CTRI/2009/091/000601已完成1 期
A Phase I, Double-blind, Placebo-controlled, Randomized, Multiple-dose, Dose-ascending Study to Evaluate the Safety, Tolerability, Pharmacokinetics and to explore Pharmacodynamic trends after oral administration of TRC150094 in Overweight/Obese Male and Female Subjects with other non traditional CV risk factors.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Medical history, physical examination, vital signs, clinical laboratory tests, 12-lead ECG and Chest X ray without significant abnormalities, in the opinion of the investigator
- •2. Overweight/obese adult male and female in the age range 18-65 years, inclusive, with a BMI in the range 27-35 kg/m2, inclusive
- •3. Waist circumference: men more than or equal to 90 cm, women more than or equal to 80 cm
- •4. Subjects with Non-alcoholic Fatty liver Grade 1-3 based on Magnetic Resonance Spectroscopy. (Ref Qayyum A)
- •5. Fasting serum insulin more than or equal to 10mU/ml and Fasting plasma glucose >100 mg/dl
- •6. Blood pressure: SBP more than or equal to 130 mmHg or DBP more than or equal to 85 mmHg or subjects
- •receiving anti-hypertensive treatment
- •7. Serum triglyceride (fasting) more than or equal to 150 mg/dL
- •8. Female subjects will include with/without childbearing potential using highly effective method of contraception except OCPs from at least 15 days prior to enrolment till 10 days after administration of last dose.
- •9. Negative drugs of abuse test and negative alcohol breath test
- •10. Non-smokers or current smokers who have been smoking less than 10 cigarettes (or equivalent) per day on a stable basis for at least 3 months prior to Day 1 and who are willing to stop smoking / tobacco intake during the study period(s).
- •11. Ability to communicate well with the investigator and to comply with the requirements of the entire study.
- •12. Willingness to give written informed consent (prior to any studyrelated procedures being performed) and ability to adhere to the study restrictions and assessments schedule.
排除标准
- •1. Clinically relevant abnormal physical findings at the screening
- •examination, which would interfere with the objectives of the study.
- •2. Clinically significant abnormalities in the results of the clinical
- •laboratory tests (at screening or Day (-1).
- •3. eGFR < 60 mL/min/1.73m2 as evaluated by Modification of Diet in Renal Disease (MDRD) method.
- •4. History of angina, Myocardial Infarction (MI) or stroke since last 6 months.
- •5. Angina or evidence of myocardial ischemia in ECG during CPET
- •6. Severe joint disease or peripheral arterial disease sufficient to impede exercise testing
- •7. Clinically relevant abnormalities in the 12-lead ECG (at screening or Day -1).
- •8. Hypertension with SBP/DBP more than or equal to 170/110 m Hg.
- •9. ALT or AST more than or equal to ULN*3
- •10. History or presence of malignancy.
- •11. Addiction to alcohol or history of any alcohol or drug abuse.
- •12. History of allergy to the test drug or any drug chemically similar to the drug under investigation.
- •13. Positive for HIV I, HIV II, hepatitis C antibody or HBsAg.
- •14. Positive for urine drugs of abuse test (at screening or Day -1).
- •15. Subjects suffering from any psychiatric (acute or chronic) illness.
- •16. Intake of any medication except those permitted in this study
- •17. Intake of any investigational drug in the period within 3 months prior to the first dose of study drug.
- •18. History of significant blood loss due to any reason, including blood donation, in the 12 weeks prior to the first dose of study drug; or the total blood loss in the last 3 months, including for this study, exceeds 450 mL.
- •19. History of any bleeding disorder.
- •20. Existence of any surgical or medical condition which, in the judgment of the principal investigator, might interfere with the absorption, distribution, metabolism or excretion of the study drug or might be likely to compromise the safety of the subject.
- •21. Inability to communicate or co-operate with the investigator because of language problems, poor mental development or impaired cerebral function.
研究者
相似试验
已完成
1 期
A Phase 1, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PRAX-114 in Healthy SubjectsNeurological - EpilepsyEpilepsyACTRN12618000650291Praxis Precision Medicines Australia Pty Ltd46
已完成
1 期
A Phase I study of inhaled PB01 in healthy male volunteers to assess the anti-inflammatory effects of PB01 on lung inflammation.Airway inflammation and fibrosisRespiratory - Other respiratory disorders / diseasesACTRN12616000496415Paranta Biosciences Ltd24
进行中（未招募）
1 期
Single Ascending-dose Study of Injectable Favipiravirsevere fever with thrombocytopenia syndromeJPRN-jRCT2071210042Sakurai Tsutomu50
招募中
1 期
A Phase I Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers under Single Ascending Dose and Multiple Ascending Dose conditions.CTRI/2022/08/045056Godavari Biorefineries Ltd
进行中（未招募）
1 期
Multiple-dose Study of Injectable Favipiravirsevere fever with thrombocytopenia syndromeJPRN-jRCT2071210126Sakurai Tsutomu24